We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Nanoscience | LSE:NAN | London | Ordinary Share | KYG6390E1070 | ORD 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4.375 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
15/4/2008 07:40 | It will be interesting to see the credentials of the new board member,I hope its someone from the semiconductor/med.de | spekky | |
14/4/2008 21:32 | Once adopted, it wa always going to be the case that controlling scale and growth would be the key management challenges. If they get that right, well, name your price. | the drewster | |
14/4/2008 15:55 | I wonder if Cambridge County Council is the authority which has signed up to MyAmego.View the CCC video to see and hear how much councils are doing to enable care at home.Thats an item from last years event so perhaps theres a chance of MyAmego getting some video coverage at this years (end of April).Come on you Sentinel PR guys/gals,start plugging the idea with Naidex TV.It was interesting to read Guys comments that no part of Sentinel is up for grabs anytime soon,must have high expectations of it. "We believe the opportunity to develop this business is substantial, both as an outlet for Toumaz product and forSentinel's own technology in other geographies. There is no intention of selling any part of the business and, in fact, we remain open to further investment aimed at the expansion of specific commercial opportunities." | spekky | |
11/4/2008 09:41 | spekky - thanks - I had read that, but your memory's obviously better than mine - not hard these days, lol. I'll read it again this evening. | supernumerary | |
11/4/2008 09:34 | Agreed. And although this is currently a European initiative the outcome will have worldwide relevance and further enhance the Toumaz reputation (and royalties). | spekky | |
11/4/2008 09:21 | This is also my biggest holding, have been here since it floated and i still beleive this has the potential to be my best investment yet, a ten bagger from here. | the shuffle man | |
11/4/2008 09:10 | Found it,its to do with a "silicon pancreas chip" which adds "intelligence" to an implanted insulin pump. PAGES 35 to 37 if your interested. | spekky | |
11/4/2008 09:06 | This is my biggest holding of all, I have great hopes for the SP, the company have some great joint ventures and the technology is fast moving. We should not be subjected to great swings in the price as the stock seems to be under the radar of the traders. | a2584728 | |
11/4/2008 08:50 | I think those who are "recurrently hospitalised" will need to have an implanted insulin delivery system which is then monitored non intrusively after the initial operation.I'm sure Chris Toumazou described this in his speech to the Royal Society last year (I seem to recalL posting a link to the PDF) | spekky | |
11/4/2008 08:42 | through the digital plaster powered by Sensium Technology | the shuffle man | |
11/4/2008 08:33 | How do you check glucose levels non-intrusively? | supernumerary | |
11/4/2008 08:33 | Happy to be wrong....doh! Just shows what a proper RNS can do,as opposed to the usual inconspicuous nature of NANs releases thru' PRN or TFN. | spekky | |
11/4/2008 08:22 | Yes it does. Nanoscience Inc 11 April 2008 Nanoscience Inc. ('Nanoscience' or the 'Group') Toumaz Technology As Part of Consortium That Wins 7.1 million European Community Grant Nanoscience, the specialist niche investor in emerging technologies with strong commercial propositions for the healthcare and electronic sectors, is pleased to announce that its wholly-owned subsidiary Toumaz Technology Limited ('Toumaz'), is part of a major collaborative research project that has been awarded a 7.1 million grant to fund the development of a portable blood glucose predictor system for diabetes patients. The Personal Glucose Predictive Diabetes Advisor ('DIAdvisorTM') system is a unique personalised blood glucose prediction tool that allows patients at any time to actively and accurately predict their short-term blood glucose outlook by the analysis of data retrieved from glucose measurements, insulin delivery data and specific patient parameters, which will be captured by non-intrusive body-worn wireless monitors based on Toumaz's breakthrough SensiumTM platform. The grant award, made under the Seventh Framework Programme (FP7) of the European Community, will fund the four-year research and development project into the DIAdvisorTM system. The large-scale project is being coordinated by Novo Nordisk A/S, a world leader in diabetes care, and will be delivered by a consortium of 13 medical, industrial and academic partners, including the European Division of the International Diabetes Federation. Toumaz's role in the project will be to implement the DIAdvisorTM hardware and software platform, leverage the SensiumTM intelligent data acquisition platform and networking infrastructure to enable multiple vital signs measurements from non-intrusive body-worn monitors to be taken and merged with manually entered ' spot' measurements (such as food intake), providing the key data for the creation of physiological mathematical modeling, control and prediction algorithms. The resulting analysis and prediction information will then be able to be wirelessly transmitted to a healthcare provider advisory service, with recommended action and treatment advice presented to the patient via a handheld mobile device such as a Personal Digital Assistant (PDA). First stage data gathering and clinical trials are planned to start in August 2008, with initial data expected by the end of the year. Dr Alison Burdett, Director of Technology for Toumaz commented: 'With DIAdvisorTM, we will be putting a sophisticated treatment advisor in the hands of patients for the first time, empowering them in their own healthcare management and significantly reducing the likelihood of serious complications and recurrent hospitalisation due to poor glucose control. For healthcare providers, DIAdvisorTM will have a significant positive impact on cost reduction for the treatment of diabetes.' Guy Spelman CEO of Nanoscience commented: 'This is further good news from our investment in Toumaz and its development of the SensiumTM platform. Recognition of the growing importance of the SensiumTM platform in more sectors in the field of medicine provides further evidence of its versatility and increasing acceptance across global leaders and government bodies.' - Ends - | papalpower | |
11/4/2008 08:17 | Market seems to like the news :-) | the shuffle man | |
10/4/2008 17:46 | The Shuffle Man That had already been flagged up at the last results (see below) although there is more detail now. "5. Key achievementsTwo strong commercial partners, establishing a clear routes to market- Major industry recognition and awards during 2007- Key commercial member, along with Novo Nordisk, of consortium awarded 7.6 million Euros under an EU Framework 7 Project "DiAdvisor" to develop new tools for the treatment of diabetes" Still,any publicity that might arise from this could be a shot in the arm for the share price Unfortunately the announcement has n't even made PR Newswire so dont expect the share price to move north just yet. | spekky | |
10/4/2008 16:50 | Toumaz Technology and Consortium Partners Win Major EU Funding To Develop Personal Blood Glucose Predictor For Diabetes Patients have a look on the web site | the shuffle man | |
20/3/2008 11:23 | Correct, I have now :) | ianood | |
20/3/2008 09:47 | ianood I presume you haven't read the Final Results properly. | spekky | |
20/3/2008 09:13 | Spekky, I think you are bang on with the new name, its a pity they won't / can't announce it formally. | ianood | |
20/3/2008 09:13 | Sensium chips shipping in production volumes in July 2008. | the shuffle man | |
20/3/2008 07:15 | consideration of a Nasdaq quote for Toumaz.?????? The Drewster - 6 Mar'08 - 21:31 - 370 of 395 If it is OMX/Nasdaq, then I would say again, it might be significant that they take a stake. I think that counts as a nail on the head Drewster...........g BTW...Just google "fortune 100" and look at the top twenty,my inkling was Medtronic and I could n't be more gloriously/massively incorrect (Med. dont make the 500 never mind top twenty).To put it in perspective,Microsof | spekky | |
19/3/2008 14:56 | Same again today? and regular rollovers appearing. | spekky | |
19/3/2008 14:38 | A good read & chuckle. | mindymaru |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions